Open Nav

DelNova, Inc.

  • Mary Gardner, DelNova, Inc.

Secure Investors for Next Round of Financing

  • Date:Wednesday, October 17
  • Time:3:15 PM - 3:30 PM
  • Room:Elizabethan D
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:To develop Innovative Therapies that resolve patient unmet needs using novel drug delivery strategies.
  • Company
  • Company HQ City:Chicago Il
  • Company HQ Country:United States
  • Company HQ State:Illinois                        
  • CEO/Top Company Official:Mary Gardner, CEO
  • Year Founded:2016
  • Main Therapeutic Focus:Dermatology
  • Lead Product in Development :ReViVox(TM)
  • Development Phase of Primary Product:Pre-Clinical
  • Number Of Unlicensed Products (For Which You Are Seeking Partners) :2
  • Additional Information/Comments:DelNova is applying drug delivery expertise to develop a repurposed drug product for reversal of side effects caused by off-target muscle paralysis induced by neurotoxins, specifically botulinum-Type A toxins (e.g. Botox™) – patent pending. There is no competitor. This is a serious problem both in cosmetic and medical applications. Although these are temporary (lasting weeks to months), this is a significant quality of life issue. Neurotoxins represent a $4 Billion dollar market worldwide with expanding medical indications. Preclinical studies are ongoing at UCSD. CROs are engaged in studies to support drug formulation and CMC. A consulting firm has been retained to conduct market research and manage regulatory/clinical aspects of the program.
  • Previous and Current Investors:BioBrit LLC, Rosetta Family Investments LLC, Steve Damon, Mary Gardner
  • Size of Last Investment Round:$750,000
  • Total Amount Raised to Date, In All Rounds:$920,000
Mary Gardner
DelNova, Inc.